News

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Top Stock Movers Now: Dayforce, Novo Nordisk, First Solar, and More

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

Stocks to Watch Monday: Novo Nordisk, TeraWulf, UnitedHealth, Soho House

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a [form of liver disease]( ...

GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They’re Offering Ozempic for $499 a Month.

Shares of GoodRx were spiking 35% on Monday. The announcement followed news from Novo Nordisk that the Food and Drug ...

Wall Street sees new obesity pills as priced near Wegovy and Zepbound

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...
Zacks.com on MSN3d

Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...
Medical Dialogues3d

Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly

Johannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's ...